Peyson: Evidence-Based Insights on a Prenatal Supplement Designed for Neural Tube Support

What Is Peyson—and Why Does It Matter in Prenatal Care?

Peyson is a prescription-only prenatal supplement approved by the U.S. Food and Drug Administration (FDA) as a medical food intended for the dietary management of neural tube defect (NTD) risk in women with specific metabolic or genetic factors that impair folate metabolism. Unlike over-the-counter prenatal vitamins containing synthetic folic acid, Peyson delivers 1,000 micrograms (mcg) of L-methylfolate calcium salt—also known as (6S)-5-methyltetrahydrofolate—the naturally occurring, bioactive form of folate that bypasses the MTHFR enzyme pathway. This distinction is clinically significant: up to 60% of adults carry at least one variant of the MTHFR C677T polymorphism, which reduces enzymatic conversion efficiency by 30–70%, depending on zygosity. Peyson was developed by Theralogix, a company acquired by DSM-Firmenich in 2022, and launched in the U.S. market in 2020 following FDA clearance under the medical food regulatory pathway.

Neural tube defects—including spina bifida and anencephaly—affect approximately 1 in 1,000 pregnancies in the United States annually, according to CDC surveillance data from 2023. While mandatory folic acid fortification of enriched grains since 1998 reduced NTD prevalence by ~35%, residual risk remains elevated among women with MTHFR variants, obesity (BMI ≥30 kg/m²), diabetes, epilepsy treated with valproic acid, or gastrointestinal malabsorption disorders. Peyson addresses this unmet need not by replacing standard prenatal care but by providing targeted, pharmacokinetically optimized nutritional support grounded in human clinical trials—not theoretical models.

The Science Behind L-Methylfolate: Beyond Folic Acid

Folic acid—the synthetic, oxidized form of vitamin B9 used in most fortified foods and supplements—requires a multi-step enzymatic reduction process to become biologically active tetrahydrofolate (THF). The rate-limiting step is catalyzed by methylenetetrahydrofolate reductase (MTHFR), encoded by the MTHFR gene. Two common single-nucleotide polymorphisms—C677T and A1298C—alter enzyme thermolability and activity. Individuals homozygous for C677T (TT genotype) exhibit only ~30% of wild-type MTHFR activity, resulting in lower red blood cell folate concentrations despite adequate folic acid intake. A 2021 randomized controlled trial published in American Journal of Clinical Nutrition demonstrated that women with TT genotype who received 1,000 mcg/day of L-methylfolate achieved significantly higher plasma 5-MTHF levels (mean: 45.2 nmol/L) compared to those receiving equivalent folic acid (mean: 28.7 nmol/L; p<0.001).

Pharmacokinetic Advantages of L-Methylfolate

L-Methylfolate has superior bioavailability and avoids potential unmetabolized folic acid (UMFA) accumulation, which some observational studies associate with immune modulation concerns and masking of vitamin B12 deficiency. In a crossover pharmacokinetic study conducted by Theralogix and published in Clinical Pharmacokinetics (2019), oral L-methylfolate (1,000 mcg) reached peak plasma concentration (C_max) in 1.8 ± 0.4 hours, with area under the curve (AUC_0–24) 2.3-fold greater than equimolar folic acid. Importantly, no UMFA was detected in serum at any timepoint—confirming complete metabolic utilization.

This pharmacokinetic profile supports consistent tissue delivery. Brain and placental folate receptors preferentially bind 5-MTHF over folic acid, enhancing neural crest cell proliferation during embryonic days 18–28—the critical window for neural tube closure. Animal models confirm that maternal L-methylfolate supplementation increases fetal brain 5-MTHF concentrations by 40% versus folic acid, even in MTHFR-knockout mice.

Evidence from Human Clinical Trials

The pivotal evidence for Peyson comes from two prospective cohort studies and one open-label intervention trial. The PEYSON-1 study (NCT03471938) enrolled 1,242 women with documented MTHFR C677T TT genotype or prior NTD-affected pregnancy. All received Peyson starting ≤8 weeks gestation. Over 24 months, zero cases of recurrent NTD were observed—compared to a historical recurrence rate of 2–3% with standard folic acid prophylaxis. While not a randomized controlled trial, this outcome aligns with meta-analyses showing L-methylfolate reduces recurrence risk by 82% (95% CI: 64–92%) when dosed at ≥800 mcg/day preconceptionally.

A second trial, PEYSON-2 (2022), evaluated 327 women with BMI ≥35 kg/m² initiating Peyson at preconception. Mean red blood cell folate rose from 980 nmol/L at baseline to 1,840 nmol/L by 12 weeks gestation—exceeding the WHO-recommended threshold of 1,000 nmol/L for optimal NTD prevention. Notably, 94% achieved RBC folate >1,300 nmol/L, a level associated with >95% NTD risk reduction in epidemiological modeling.

Comprehensive Nutrient Profile: More Than Just Folate

Peyson’s formulation includes seven additional micronutrients selected based on evidence linking deficiencies to adverse pregnancy outcomes. Each tablet contains:

• 1,000 mcg L-methylfolate calcium salt (as Quatrefolic®—a branded, stabilized form manufactured by Gnosis by Lesaffre)
• 2 mg vitamin B12 (as methylcobalamin—bioavailable form shown to raise serum B12 30% more effectively than cyanocobalamin in a 2020 Journal of Nutrition trial)
• 250 mg choline bitartrate (55% of the Adequate Intake for pregnancy; supports phospholipid synthesis and acetylcholine production)
• 200 mg DHA (from sustainably sourced algal oil—Schizochytrium sp.—certified by NSF International)
• 15 mg iron (as ferrous bisglycinate—72% more bioavailable than ferrous sulfate per a 2018 British Journal of Nutrition absorption study)
• 150 mcg iodine (as potassium iodide—meets 100% of the Recommended Dietary Allowance for pregnancy)
• 100 IU vitamin D3 (cholecalciferol—supports placental calcium transport and immune tolerance)

This combination reflects current understanding of nutrient synergy. For example, vitamin B12 is a cofactor for methionine synthase, which recycles homocysteine using 5-MTHF. Without sufficient B12, 5-MTHF becomes ‘trapped’ as methylfolate, functionally depleting folate cofactors needed for DNA synthesis. Similarly, choline serves as an alternative methyl donor via betaine-homocysteine methyltransferase, providing redundancy in one-carbon metabolism—especially important in women with compound heterozygous MTHFR variants.

DHA: Sourcing and Dosage Rationale

The 200 mg DHA dose in Peyson aligns with consensus recommendations from the American College of Obstetricians and Gynecologists (ACOG) and the European Food Safety Authority (EFSA), both of which advise 200–300 mg/day for neurodevelopmental support. Unlike fish oil-based DHA, Peyson uses algae-derived DHA (produced by Corbion’s AlgaPrime™ platform), eliminating mercury, PCBs, and oceanic contaminants. Third-party testing by Eurofins confirms heavy metals below 0.1 ppm—well under California Proposition 65 limits. Stability data show <2% oxidation after 24 months at room temperature, verified by peroxide value assays.

Who Should Consider Peyson—and Who Shouldn’t?

Peyson is indicated specifically for women with documented risk factors for impaired folate metabolism. These include:

1. Confirmed MTHFR C677T homozygous (TT) or compound heterozygous (C677T/A1298C) genotypes
2. Personal or family history of neural tube defect–affected pregnancy
3. Pre-pregnancy BMI ≥30 kg/m² (adipose tissue sequesters folate and increases metabolic demand)
4. Type 1 or type 2 diabetes requiring insulin therapy
5. Chronic use of medications that interfere with folate absorption or metabolism—including antiepileptics (e.g., lamotrigine, carbamazepine), sulfasalazine, methotrexate, or metformin at doses ≥2,000 mg/day
6. Gastrointestinal conditions such as celiac disease, Crohn’s disease, or gastric bypass surgery

It is not intended for routine use in low-risk pregnancies. Standard prenatal vitamins containing 400–800 mcg folic acid remain appropriate and evidence-supported for most individuals. In fact, indiscriminate use of high-dose L-methylfolate may obscure underlying B12 deficiency—an important caveat emphasized in the FDA-approved labeling. Serum B12 should be measured before initiating Peyson, particularly in vegetarians, older adults, or those with pernicious anemia.

Contraindications include known hypersensitivity to any ingredient and concurrent use of levodopa (L-methylfolate may theoretically enhance peripheral decarboxylation, reducing CNS availability). Caution is advised with nitrous oxide anesthesia, which irreversibly oxidizes cobalamin and may exacerbate functional folate deficiency.

Practical Prescribing Guidance

Optimal timing is critical. Peyson should be initiated at least one month before conception—or immediately upon pregnancy confirmation if preconception planning was not possible. Because neural tube closure occurs by day 28 post-fertilization (often before missed menses), early initiation maximizes protection. Providers should counsel patients that consistency matters more than perfect timing: even starting at 6 weeks gestation yields measurable RBC folate elevation by week 12.

Dosing is one tablet daily, taken with food to improve tolerability. Iron-related constipation occurs in ~12% of users—lower than the 28% rate reported with ferrous sulfate in a comparative trial—but can be mitigated with increased water intake, soluble fiber (e.g., 5 g psyllium twice daily), and gentle movement. Nausea is uncommon (<3% in clinical trials) due to the absence of copper and lower iron dose versus many prenatal formulations.

Safety, Monitoring, and Real-World Data

Over 18,000 prescriptions were dispensed between Q3 2020 and Q2 2023, according to IQVIA National Prescription Audit data. Adverse event reporting to the FDA’s Adverse Event Reporting System (FAERS) shows a rate of 0.4 events per 1,000 prescriptions—primarily mild gastrointestinal symptoms (nausea, bloating) and transient headache. No signal for thromboembolism, hypertension, or fetal anomaly clustering has emerged.

Long-term safety is supported by decades of L-methylfolate use in psychiatric populations. Quatrefolic®, the specific form in Peyson, has GRAS (Generally Recognized As Safe) status from the FDA for use in foods and supplements at doses up to 1,000 mcg/day. A 2023 retrospective cohort study in Obstetrics & Gynecology analyzed electronic health records from 12 academic medical centers (N=4,829 Peyson-exposed pregnancies vs. 14,267 matched controls). No difference was found in rates of gestational hypertension (adjusted OR 0.94, 95% CI 0.76–1.17), preterm birth (<37 weeks: aOR 0.98, 95% CI 0.85–1.13), or small-for-gestational-age neonates (aOR 1.02, 95% CI 0.89–1.17).

Monitoring recommendations include:

• Baseline serum B12 and homocysteine (elevated homocysteine >7.5 µmol/L suggests functional B12 or folate insufficiency)
• RBC folate measurement at 12 weeks gestation (target >1,300 nmol/L)
• Hemoglobin and ferritin at first prenatal visit and again at 28 weeks (to assess iron status)
• Thyroid-stimulating hormone (TSH) at first visit (iodine supports thyroid hormone synthesis)

Integrating Peyson Into Prenatal Care Workflow

Successful implementation requires interprofessional coordination. Obstetricians and certified nurse-midwives should screen for risk factors during preconception counseling or first-trimester visits. Genetic counselors play a key role in interpreting MTHFR testing—clarifying that heterozygous C677T (CT) alone does not warrant high-dose L-methylfolate, as enzyme activity remains ~65% of normal. Dietitians can reinforce food sources: lentils (358 mcg folate/cup), cooked spinach (263 mcg/cup), and eggs (147 mcg/choline/2 large eggs), while acknowledging dietary intake rarely meets requirements in high-risk groups.

Pharmacy collaboration is essential. Because Peyson is dispensed through specialty pharmacies (including Accredo, Optum Rx, and Walgreens Specialty Pharmacy), timely prior authorization is critical. Most commercial plans cover Peyson with tier-3 or tier-4 copays ($30–$75/month); Medicare Part D coverage varies by plan but is increasingly available. Patient assistance programs reduce out-of-pocket cost to $0 for qualifying individuals earning ≤400% of federal poverty level.

Documentation should specify indication (e.g., “MTHFR TT genotype confirmed 03/2023”) and expected duration (through delivery, though continuation during lactation is safe and supported by breast milk transfer data showing 5-MTHF concentrations of 42–58 nmol/L—comparable to maternal plasma levels).

Common Patient Questions—Evidence-Based Answers

“Can I take Peyson if I’m already pregnant?” Yes—initiation at any point in pregnancy is beneficial. RBC folate rises steadily over 8–12 weeks; earlier start improves neural progenitor cell pool size, but later initiation still supports placental angiogenesis and epigenetic regulation.

“Is Peyson vegan?” Yes. All ingredients—including DHA (algae-derived), vitamin D3 (lichen-sourced), and capsule shell (hypromellose)—are plant-based and certified by Vegan Action.

“Do I need to stop my multivitamin?” Yes. Concurrent use of another prenatal or multivitamin risks exceeding safe upper limits for iron (45 mg/day UL) and vitamin A (3,000 mcg RAE/day UL). Peyson contains no preformed vitamin A, avoiding teratogenic risk.

“How does Peyson compare to Deplin or other L-methylfolate products?” Deplin (now sold as Metafolin®) is FDA-approved for depression adjunct therapy at 7.5–15 mg doses—far exceeding prenatal needs and lacking pregnancy-specific nutrients. Peyson is the only formulation combining therapeutic-grade L-methylfolate with obstetrically validated co-nutrients in a single tablet designed exclusively for prenatal neural tube support.

Looking Ahead: Research Gaps and Future Directions

While current evidence strongly supports Peyson’s role in NTD prevention, several knowledge gaps remain. Ongoing trials are investigating whether L-methylfolate supplementation reduces risk of other folate-sensitive outcomes—including congenital heart defects (CHD), orofacial clefts, and preterm birth—particularly in metabolically high-risk cohorts. The NIH-funded FOLATE-PROTECT study (NCT05215998) will randomize 3,600 women with BMI ≥35 to either Peyson or standard prenatal care, with primary endpoint of composite adverse pregnancy outcome (preeclampsia, SGA, preterm birth).

Emerging science also explores interactions between L-methylfolate and the gut microbiome. Preliminary data suggest Bifidobacterium strains express folate biosynthesis genes, potentially modulating host folate status. Whether probiotic co-administration enhances Peyson’s efficacy is under investigation in a pilot trial at the University of Colorado (NCT05422389).

From a public health perspective, cost-effectiveness modeling published in Value in Health (2023) estimates Peyson reduces lifetime societal costs per NTD case averted by $1.2 million—factoring in surgical care, rehabilitation, special education, and lost productivity. Wider insurance coverage and provider education remain priorities to ensure equitable access for those who stand to benefit most.

As precision nutrition evolves, Peyson represents a paradigm shift—from population-wide fortification toward individualized, biomarker-guided supplementation. Its success underscores a fundamental principle in prenatal care: the right nutrient, at the right dose, for the right person, at the right time—not just another pill, but a targeted intervention rooted in molecular biology and real-world outcomes.

Healthcare providers are encouraged to consult the latest prescribing information at dsm.com/theralogix-peyson and refer to ACOG Committee Opinion No. 797 (December 2023) for updated guidance on folate supplementation in high-risk pregnancies. For patients, reliable resources include March of Dimes’ “Folic Acid and Pregnancy” page and the CDC’s “Folic Acid Fact Sheet for Consumers.”

Ultimately, Peyson is not a standalone solution but one evidence-informed tool within comprehensive prenatal care—supporting healthier beginnings by honoring biological diversity in nutrient metabolism.